Advertisement
  • Q&A

    Hope Amid the Hype

    Hematologist-oncologist David Scadden traces the history, promise and uncertainties of treatment advances in Cancerland: A Medical Memoir.

    by Marci A. Landsmann

  • First Immunotherapy Approved for Breast Cancer

    Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

    by Anna Azvolinsky

  • Holding Off on Treatment

    Patients diagnosed with low-risk prostate cancer are increasingly opting against immediate surgery or radiation in favor of regularly monitoring their disease.

    by Jon Kelvey

  • Young Colorectal Cancer Patients Are Often Misdiagnosed

    A new survey suggests that young adults with colorectal cancer struggle to receive an accurate, prompt diagnosis.

    by Bradley Jones

  • Making Clinical Trials More Inclusive

    Broadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.

    by Ashley P. Taylor

  • What Do Clinical Trial Endpoints Really Measure?

    A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.

    by Jon Kelvey

  • Treating Breast Cancer in Men

    Hormone therapy may lengthen life in men with hormone-related breast cancer, but this treatment is prescribed less frequently for men than for women.

    by Marilyn Fenichel

  • Forward Look

    What’s Next? Winter 2018/2019

    Off-the-shelf equivalents to CAR-T cell therapy are emerging.

    by Bradley Jones

  • From the Editor-in-Chief

    Improving Health After Treatment

    The U.S. health care system must adapt to the needs of cancer survivors.

    by William G. Nelson, MD, PhD

  • Getting a Read on Cancer

    Cancer patients are increasingly receiving treatments guided by the molecular characteristics of their cancer cells. But patients may have unequal access to testing and targeted therapies.

    by Kate Yandell